Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Tarantini

Vascular Surgery Union, NJ Medical Doctor

NPI 1679550578 CMS profile 121610

1050 Galloping Hill Rd Ste 102, Ste 102, Union, NJ 07083

Open in the dashboard

General payments

$4,311

120 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Tarantini of Union, NJ is reported in the CMS Open Payments database as having received $4,311 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 46th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,353 18
2024 General $705 12
2023 General $516 21
2022 General $480 15
2021 General $483 22
2020 General $434 26
2019 General $340 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Tarantini
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Frank Tarantini were reported at $1,353. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Frank Tarantini Vascular Surgery median Middle half National median
2019 $340 $796 $226–$2,363 $163
2020 $434 $348 $118–$1,110 $114
2021 $483 $471 $158–$1,421 $132
2022 $480 $725 $222–$2,183 $149
2023 $516 $836 $257–$2,440 $160
2024 $705 $909 $252–$2,619 $164
2025 $1,353 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,116 37 payments
  2. Boston Scientific Corporation $1,239 51 payments
  3. Medtronic Vascular, Inc. $435 19 payments
  4. W. L. Gore & Associates, Inc. $144 1 payment
  5. Mozarc Medical US LLC $127 1 payment
  6. Tactile Systems Technology Inc $122 4 payments
  7. Janssen Pharmaceuticals, Inc $101 6 payments
  8. Baxter Healthcare $27 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,311 120 payments
Products named General payments · program years 2019–2025
  1. HawkOne Directional Atherectomy Devices $993 15 payments
  2. ELLIPSYS VASCULAR ACCESS SYSTEM $516 4 payments
  3. HawkOne Directional Atherectomy Devices $435 19 payments
  4. ENDURANT IIS $280 5 payments
  5. Abre $227 6 payments
  6. GENERAL ULTRASOUND $171 6 payments
  7. GORE PROPATEN Vascular Graft $144 1 payment
  8. OptiCross 35 $134 7 payments
  9. PALINDROME $127 1 payment
  10. Flexitouch Plus $122 4 payments
  11. Other $1,053 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

503

Median for Interventional Radiology: 38

Drug cost

$89,023

Median for Interventional Radiology: $333

Branded share of claims

55.7%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 53 $48,983
Eliquis Apixaban Brand 32 $35,049
Cephalexin Generic 62 $1,410
Clopidogrel Clopidogrel Bisulfate Brand 130 $1,388
Cilostazol Generic 43 $928
Duloxetine Hcl Generic 38 $548
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 18 $183
Celecoxib Generic 38 $145
Gabapentin Generic 17 $127
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 47 $121

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 92 billing codes

Paid by Medicare

$1,435,602

Of which drugs: $5,647

Medicare patients

697

Average age 74

Services billed

13,136

326 women, 371 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 73%
Arthritis 54%
Ischemic heart disease 52%
Chronic kidney disease 49%
Heart failure 28%
COPD 25%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, alteplase recombinant, 1 mg J2997 Office 14 61 $4,310
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 144 9,410 $967
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 38 1,270 $370

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record